We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration Agreement Targets Tumor-Related Genes

By LabMedica International staff writers
Posted on 02 Feb 2015
A German biomedical company has entered into a collaborative agreement with a major Norwegian hospital that focuses on the identification of cancer-related tumor genes that predict a patient’s response or resistance to targeted therapies.

The German biomedical company New Oncology (Cologne, Germany) has announced the establishment of a collaborative agreement with University Hospital Oslo (Norway). More...
New Oncology will apply its proprietary diagnostic platform "NEO" to the problem of identifying cancer-related tumor genes that predict a patient’s response or resistance to targeted therapies.

The "NEO" diagnostic platform enables physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. The cancer diagnostic test NEOplus, which is available through certified pathologists, is an efficient, time-saving diagnostic assay that enables parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days NEOplus detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA. In addition, NEOplus is suited to analyzing all solid tumor types.

Physicians receive a detailed medical report within 10–15 working days after receipt of the patient’s sample. The medical report suggests suitable targeted therapies and an individualized recommendation for treatment if actionable genetic alterations are identified. In addition to treatment options, the report also provides information on relevant clinical trials.

“Dramatic responses to targeted therapies in patients with advanced solid tumors bearing drug-sensitizing mutations have shifted the paradigm of cancer treatment towards a comprehensive molecular characterization before initiation of treatment. The growing number of targeted drugs, different types of targetable genome alterations, and the occurrence of resistance mechanisms are increasing challenges for clinical diagnostics. Technological and computational advances in the field of tumor diagnostics finally put us in the position to perform comprehensive, sensitive and fast analysis of all different types of genome alterations on routine tumor specimens. This is a pivotal step in matching the right patients with the right drugs, providing broad access to personalized cancer medicine to all patients,” said Dr. Roman Thomas, professor of cancer genomics at the University of Cologne (Germany) and a founder of New Oncology.

Related Links:

New Oncology
University Hospital Oslo
University of Cologne



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.